Results 191 to 200 of about 549,653 (268)
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler +4 more
wiley +1 more source
Gut microbiota and fecal 2-methylbutyric acid in coronary heart disease: a cross-sectional study. [PDF]
Dechkhajorn W +5 more
europepmc +1 more source
Chronic Diseases and Translational Medicine, EarlyView.
Serafino Fazio, Flora Affuso
wiley +1 more source
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen +4 more
wiley +1 more source
Prevalence and risk factors of cognitive impairment in patients with coronary heart disease: a systematic review and meta-analysis. [PDF]
Han J, Xie B, Zhao N.
europepmc +1 more source
MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio +10 more
wiley +1 more source
Identification and validation of mitochondrial metabolism-ralated biomarkers in coronary heart disease. [PDF]
Zhao X, He J.
europepmc +1 more source
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Ginsenoside Rh2 Regulates PI3K/AKT Signaling, Metabolic Pathways, and the Gut Microbiota for Coronary Heart Disease Therapy. [PDF]
Chen Z +5 more
europepmc +1 more source
Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi +4 more
wiley +1 more source

